US AD costs: $91B to $189B over 10 years
A US patient group has reported that there are now five million sufferers of Alzheimer's disease and that the cost to the Medicare health care program will increase from $91.0 billion in 2005 to $189.0 billion in 2015.
The Alzheimer's Association has issued a report, titled 2007 Alzheimer's Disease Facts and Figures, to coincide with the association's annual Public Policy Forum, in Washington DC, March 18-20. The group warns that if no cure is discovered and with the aging "baby boomer" generation beginning to reach 60 years, when the incidence of AD increases, the number of sufferers could reach 7.7 million people in the USA.
"There are currently nine drugs in Phase III clinical trials for Alzheimer's, several of which show great promise to slow or stop the progression of the disease," according to Harry Johns, the Alzheimer's Association president.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze